ELiBio

DIGITAL LIVER BIOPSY

Non-invasive MRI examination
Early diagnosis of MASH disease

90%

MASH PATIENTS NOT
DETECTED AT EARLY-STAGE

1 in 3

ADULT WORLDWIDE
SUFFERS LIVER STEATOSIS

75%

RECOVERY
AFTER TREATMENT

1 in 20

ADULT GLOBALLY ESTIMATED
TO LIVE WITH MASH

1st

LEADING CAUSE OF
CHRONIC LIVER DISEASE

Up to 40x

HIGHER RISK OF LIVER COMPLICATIONS IN ADVANCED FIBROSIS OR CIRRHOSIS PATIENTS

1 in 4

LIVER CANCER IS A MAFLD CASE

80%

OF MASH PATIENTS
NOT DIAGNOSED IN THE UK

+63%

INCREASE IN MASH PATIENTS
IN THE US BETWEEN 2015 AND 2030

+13 K€

YEARLY COST PER PATIENT AFFECTED BY MASH IN EUROPE

OUR SOLUTION : ELiBio^®

Our non-invasive diagnostic imaging tool allows early detection of patients at risk of MASH using MRI.

Access to rapid and easy to understand reports helps clinicians enhance patient care.
Our solution is also useful in pharmaceutical industry to evaluate effects of drugs on the liver health.

WHO ARE WE?

SoQut-Imaging is a young IT deep tech start-up specialized in MRI quantitative imaging. We revolutionize the clinical diagnosis and management of patients who suffer Fatty Liver Disease with our proprietary technology ELiBio^®.

« Our ambition is to provide Hospitals with the reference method for diagnosis and management of chronic liver diseases, working as close as possible to the patients who need it. »

Benoît Chardonnet

Co-Founder - CEO

Simon Lambert, PhD

Co-Founder - Scientific Advisor

Benjamin Leporq, PhD

Co-Founder - Scientific Advisor

Renaud Winzenrieth, PhD

Co-Founder - CCO & RA

Benoit Recur, PhD

CTO

Laureen Ferchaud

CCO

Hugo Balacey, PhD

Lead Dev

Learn more about the team

ELiBio

DIGITAL LIVER BIOPSY

Non-invasive MRI examination
Early diagnosis of MASH disease

OUR SOLUTION : ELiBio^®

Our non-invasive diagnostic imaging tool allows early detection of patients at risk of MASH using MRI.

Access to rapid and easy to understand reports helps clinicians enhance patient care.
Our solution is also useful in pharmaceutical industry to evaluate effects of drugs on the liver health.

WHO ARE WE?

SoQut-Imaging is a young IT deep tech start-up specialized in MRI quantitative imaging. We revolutionize the clinical diagnosis and management of patients who suffer Fatty Liver Disease with our proprietary technology ELiBio^®.

« Our ambition is to provide Hospitals with the reference method for diagnosis and management of chronic liver diseases, working as close as possible to the patients who need it. »

WANT TO LEARN MORE ?

Contact ELiBio team

ELiBio

DIGITAL LIVER BIOPSY

Non-invasive MRI examination Early diagnosis of MASH disease

OUR SOLUTION : ELiBio®

Our non-invasive diagnostic imaging tool allows early detection of patients at risk of MASH using MRI.

Access to rapid and easy to understand reports helps clinicians enhance patient care. Our solution is also useful in pharmaceutical industry to evaluate effects of drugs on the liver health.

WHO ARE WE?

SoQut-Imaging is a young IT deep tech start-up specialized in MRI quantitative imaging. We revolutionize the clinical diagnosis and management of patients who suffer Fatty Liver Disease with our proprietary technology ELiBio®.

« Our ambition is to provide Hospitals with the reference method for diagnosis and management of chronic liver diseases, working as close as possible to the patients who need it. »

WANT TO LEARN MORE ?

Contact ELiBio team

Non-invasive MRI examination
Early diagnosis of MASH disease

OUR SOLUTION : ELiBio^®

Access to rapid and easy to understand reports helps clinicians enhance patient care.
Our solution is also useful in pharmaceutical industry to evaluate effects of drugs on the liver health.

SoQut-Imaging is a young IT deep tech start-up specialized in MRI quantitative imaging. We revolutionize the clinical diagnosis and management of patients who suffer Fatty Liver Disease with our proprietary technology ELiBio^®.